logo-loader
viewOptiBiotix Health PLC

OptiBiotix Health CEO updates on new deal with Actial Farmaceutica and launch of WellBiome

OptiBiotix Health's (LON:OPTI) Stephen O'Hara caught up with Proactive London's Andrew Scott following the news they've signed a distribution deal covering Australia, New Zealand, Indonesia, and Thailand for its cholesterol and blood pressure reducing dietary supplements, CholBiome and CholBiome X3. It's with Actial Farmaceutica - an Italian business with operations in Asia focused on probiotics and gut health. O'Hara also expands on the announcement from earlier this week around the launch of WellBiome, a blend of fibres and minerals to promote the diversity of the gut microbiome.

Quick facts: OptiBiotix Health PLC

Price: 53.2 GBX

AIM:OPTI
Market: AIM
Market Cap: £46.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

OptiBiotix Health expands key deals for its WellBiome and CholBiome

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara speaks to Proactive's Andrew Scott after announcing thy've amended its relationship with CTC Group, the company that is distributing and selling its CholBiomex3 product in the Philippines. The new agreement extends the product range from the...

2 weeks, 5 days ago

2 min read